Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TLR4 | O00206 | 2/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994061 | 1.00 | MAPK1 (0.50) | MAPK1TLR4DGKALPAR1LPAR3 | |
| SCHEMBL14010258 | 1.00 | MAPK1 (0.50) | MAPK1TLR4DGKALPAR1LPAR3 | |
| SCHEMBL4991659 | 1.00 | MAPK1 (0.50) | MAPK1TLR4DGKALPAR1LPAR3 | |
| SCHEMBL14010283 | 1.00 | MAPK1 (0.50) | MAPK1TLR4DGKALPAR1LPAR3 | |
| SCHEMBL4994069 | 1.00 | MAPK1 (0.50) | MAPK1TLR4DGKALPAR1LPAR3 | |
| SCHEMBL21137910 | 0.89 | TLR4 (0.44) | MAPK1TLR4DGKA | |
| SCHEMBL14010294 | 0.85 | MAPK1 (0.72) | MAPK1TLR4ALDH1A1THRBAKT1 | |
| SCHEMBL4996451 | 0.85 | MAPK1 (0.72) | MAPK1TLR4ALDH1A1THRBAKT1 | |
| SCHEMBL17318241 | 0.84 | TLR4 (0.51) | TLR4DGKALPAR1LPAR3AKT1 | |
| SCHEMBL18169507 | 0.84 | MAPK1 (0.48) | MAPK1TLR4DGKAALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553101-B1 | N-ACETYLGLUCOSAMINE DERIVATIVES AND USE THEREOF | KAO CORP (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20080293673-A1 | N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF | KAO CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-7393937-B2 | N-acetylglucosamine derivatives and use thereof | KAO CORPORATION (JP) | 2008-07-01 | — | — | US | disclosed |
| US-20060020127-A1 | N-acetylglucosamine derivatives and use thereof | KANEBO COSMETICS INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1553101-A1 | N-ACETYLGLUCOSAMINE DERIVATIVES AND USE THEREOF | Kanebo Cosmetics Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020127-A1 | N-acetylglucosamine derivatives and use thereof | FUT6, B3GNT2, FUT5 | MAPK1 1512/4885TLR4 891/4885DGKA 1922/4885 |
| US-20080293673-A1 | N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF | B3GNT2, FUT6, FUT5 | MAPK1 1506/4885TLR4 1032/4885DGKA 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.